Immune Checkpoint Inhibitors in Small-Cell Lung Cancer
1 Views
administrator
07/04/23
Mark Socinski, MD; Roy Herbst, MD, PhD; and Naiyer Rizvi, MD, discuss the excitement over PD-1 inhibitors in non-small–cell lung cancer. The data for pembrolizumab and that for nivolumab plus ipilimumab were equally impressive.
-
Category
Show more
Facebook Comments
No comments found